Treatment methods of cognitive, emotional and mental ailments and disorders
OwnerJack William Schultzinventor
Life of this patent
Estimating the term…
Abstract
Methods for the treatment of cognitive, emotional and mental ailments using therapeutically effective amounts of compositions including leukotriene receptor antagonists, leukotriene synthesis inhibitors or leukotriene modifiers, zafirlukasts, montelukasts, other members of the family -lukasts, zileutons.
Claims13
A method, comprising administering to a patient suffering from cognitive short term memory loss, a therapeutically effective amount of a composition comprising a member of the family -lukast, wherein the composition reverses said cognitive short term memory loss for a specified period of time for relief, said method further comprising:
- administering orally a 10 mg first dose of montelukast sodium upon awakening;
- administering a 10 mg second dose of montelukast sodium about two hours after said first dose;
- administering a 5 mg third dose of montelukast sodium about three to four hours after said second dose;
- administering a 5 mg fourth dose of montelukast sodium about three to four hours after said third dose;
- optionally administering a 10 mg fifth dose of montelukast sodium about three to four hours after said fourth dose.
A method for treating memory loss in a human comprising the steps of:
- administering to a patient with memory loss a first dosage of a therapeutically effective amount of a composition comprising montelukast sodium, wherein the initial dose of the composition comprises at least 10 mg of montelukast sodium, wherein the memory loss is not the result of ongoing allergies, and
- administering a second dosage of the composition, wherein the second dose of the composition comprises at least 5 mg of montelukast sodium, wherein the second dosage is administered between 2-4 hours after the first dosage.
A method for improving cognitive function in a human comprising the steps of:
- administering to a patient with cognitive impairment a first dosage of a therapeutically effective amount of a composition comprising montelukast sodium, wherein the initial dose of the composition comprises at least 10 mg of montelukast sodium, wherein the cognitive impairment is not the result of ongoing allergies, and
- administering a second dosage of the composition, wherein the second dose of the composition comprises at least 5 mg of montelukast sodium, wherein the second dosage is administered between 2-4 hours after the first dosage.
Dependencies are inferred from the claim text.